RemeGen Co (688331.SS) Stock Price

RemeGen Co Price

CLOSED
101.17
​
Market closed

Over the last 7 years RemeGen Co grew revenue by 124.5% annually, reaching 3.25 B CNY. For RemeGen Co, the net margin of 21.8% is up versus 19.4% a few years ago. The consensus 12-month price target for RemeGen Co is 87.06 CNY, about 13.9% below where the stock trades today. Of 11 analysts, 7 rate the stock a buy — an overall Buy consensus.

RemeGen Co stock price

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

RemeGen Co business model & stock analysis

RemeGen Co Ltd generates revenue by researching, developing, and manufacturing innovative biopharmaceuticals, specifically focusing on therapeutic antibody drugs. The company's product portfolio includes tetacept (RC18), veldicitumab (RC48), and a dual-target fusion protein (RC28). These products are designed to treat major diseases such as oncology, autoimmune diseases, and ophthalmology. The firm operates primarily in the domestic market within China, where it commercializes its discoveries. Its business model relies on the development of various antibody types, including antibody drug conjugates (ADCs), antibody fusion proteins, monoclonal antibodies, and bispecific antibodies. This focus allows the company to address significant medical needs through its specialized therapeutic offerings.

Frequently asked questions about RemeGen Co

Analysts currently set an average price target of 96.96 CNY for the RemeGen Co stock (median: 87.06 CNY), implying -4.2 % versus the latest price. The consensus is based on 11 analyst ratings.

11 analysts currently rate the RemeGen Co stock: 7 recommend buying, 3 holding and 1 selling.

Converted at the current exchange rate, the RemeGen Co share trades at 13.53 EUR (101.17 CNY).

The revenue cannot currently be calculated for RemeGen Co.

The profit cannot currently be calculated for RemeGen Co.

The P/E ratio cannot be calculated for RemeGen Co at the moment.

The P/S cannot be calculated for RemeGen Co currently.

The Eulerpool Quality Score for RemeGen Co is 4/10.

The ISIN of RemeGen Co is CNE100005B03. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of RemeGen Co is 688331.SS. The ticker symbol is used to trade RemeGen Co shares on the stock exchange.

Fair ValueTerminal
107.24 CNY
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Biotechnology
Number of shares
Employees
Revenue per Employee
975,705.58 CNY
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Website remegen.cn
Country
Currency
CNY
Initial public offering
Nov 9, 2020
ISIN
CNE100005B03
Cusip
Y7S9CK119
Market capitalization
54.42 B CNYLarge Cap
52-Week Range
PEG
1.08
P/E ratio
P/Ee 2027
71.50
P/Ee 2028
40.69
P/Ee 2029
13.92
P/Ee 2030
—
P/Ee 2031
—
P/Se
11.70
EV/EBIT
75.80
P/B Ratio
23.45
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
18.70 %
Last updated Oct 26, 2026, 10:32 AM

RemeGen Co Peer Group

RemeGen Co FIGI

688331:CH · BBG00S5K4TC7688331:CG · BBG011K9YB20688331:C1 · BBG016HSTVH7

All fundamentals and in-depth analysis of RemeGen Co

Our stock analysis for RemeGen Co stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of RemeGen Co. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.